Search Results - "Tammela, T.L.J"

P5 First screening round results of the ProScreen trial with PSA, kallikrein panel and MRI by Rannikko, A.S., Tammela, T.L.J., Mirtti, T., Lilja, H., Tolonen, T., Kenttämies, A., Rinta-Kiikka, I., Lehtimäki, T., Natunen, K., Nevalainen, J., Raitanen, J., Ronkainen, J., van der Kwast, T., Riikonen, J., Petas, A., Matikainen, M., Taari, K., Kilpeläinen, T.

Get full text

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months by Bögemann, M.W.H., Shore, N.D., Tammela, T.L.J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M-A., Snapir, A., Sarapohja, T., Fizazi, K.

Get full text

Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer by Boevee, S.J, Venderbos, L.D.F, Tammela, T.L.J, Nelen, V, Ciatto, S, Kwiatkowski, M, Páez, A, Malavaud, B, Hugosson, J, Roobol, M.J

“…Abstract Objective To evaluate a change in tumour characteristics and applied treatments over time in the control arm of all centres of the European Randomized…”
Get full text

Expected impact of MRI related interreader variability on ProScreen prostate cancer screening trial by Hietikko, R., Kilpeläinen, T.P., Kenttämies, A., Ronkainen, J., Ijäs, K., Lind, K., Marjasuo, S., Oksala, J., Oksanen, O., Saarinen, T., Savolainen, R., Taari, K., Tammela, T.L.J., Mirtti, T., Natunen, K., Auvinen, A., Rannikko, A.

Get full text

5α-reductase inhibitors use and bladder cancer-specific mortality in a Finnish population-based cohort by Mäkelä, V, Kotsar, A, Tammela, T.L.J, Murtola, T.J

Get full text

Components of metabolic syndrome and prognosis of renal cell cancer by Eskelinen, T, Kotsar, A, Tammela, T.L.J, Murtola, T.J

Get full text

7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer by Smith, M, Egerdie, B, Sieber, P, Tammela, T.L.J, Saad, F, Ke, C, Leder, B, Dansey, R, Goessl, C

Get full text

222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial by Smith, M.R., Shore, N.D., Tammela, T.L.J., Berre, M-A. Le, Petrenciuc, O., Zurth, C., Kuss, I., Fizazi, K.

Get full text

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer by Jalava, S E, Urbanucci, A, Latonen, L, Waltering, K K, Sahu, B, Jänne, O A, Seppälä, J, Lähdesmäki, H, Tammela, T L J, Visakorpi, T

“…The androgen receptor (AR) signaling pathway is involved in the emergence of castration-resistant prostate cancer (CRPC). Here, we identified several…”
Get full text

114 5-alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial by Murtola, T.J, Karppa, E.K, Taari, K, Tammela, T.L.J, Auvinen, A

Get full text

349 Risk of biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers by Murtola, T.J, Tammela, T.L.J

Get full text

Aspects of adult satisfaction with the result of surgery for hypospadias performed in childhood by Aho, M O, Tammela, O K, Tammela, T L

“…Our aim was to ascertain whether the short-term results and the frequency of complications of corrective surgery in hypospadias correlate with patients'…”
Get more information

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) by Fizazi, K., Shore, N.D., Tammela, T.L.J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Berre, M-A. Le, Petrenciuc, O., Snapir, A., Sarapohja, T., Smith, M.R.

Get full text

Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer by Urbanucci, A, Sahu, B, Seppälä, J, Larjo, A, Latonen, L M, Waltering, K K, Tammela, T L J, Vessella, R L, Lähdesmäki, H, Jänne, O A, Visakorpi, T

“…Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression…”
Get full text

13 Polymorphisms in genes of the glucose- and energy-metabolism pathways and prostate cancer: Interplay with metformin by Murtola, T.J, Wahlfors, T, Haring, A, Taari, K, Stenman, U, Tammela, T.L.J, Schleutker, J, Auvinen, A

Get full text

323 Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study by Thomsen, F.B, Brasso, K, Berg, K.D, Gerds, T.A, Johansson, J-E, Angelsen, A, Tammela, T.L.J, Iversen, P

Get full text

856 Anti-diabetic drugs and prostate cancer incidence in the Finnish Prostate Cancer Screening Trial by Haring, A, Murtola, T.J, Määttänen, L, Taari, K, Tammela, T.L.J, Auvinen, A

Get full text

266 Population level associations between COX-2 Inhibition by NSAID use and prostate cancer risk by Veitonmäki, T.P.C, Tammela, T.L.J, Auvinen, A, Murtola, T.J

Get full text

Outcomes of prostate cancer screening among men using antidiabetic medication by Vettenranta, A., Murtola, T. J., Talala, K., Taari, K., Stenman, U.-H., Tammela, T. L. J., Auvinen, A.

“…Diabetic men have decreased risk for prostate cancer (PCa) overall and lower PSA compared to non-diabetics. This may affect the outcomes of PSA-based…”
Get full text

165 Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer by Annala, M, Kivinummi, K, Tuominen, J, Latonen, L, Ylipää, A, Saramäki, O, Kaukoniemi, K.M, Karakurt, S, Yli-Harja, O, Vessella, R.L, Tammela, T.L.J, Zhang, W, Visakorpi, T, Nykter, M

Get full text